COVID-19 vaccine hesitancy is already at its peak for a number of reasons, but for some, it revolves around potential side effects of taking the vaccinations, which have been available to the public for less than a year.
According to Fox News, the Food and Drug Administration (FDA) didn’t help the situation on Tuesday, as the government agency is said to be soon announcing a stunning new warning for those who’ve received the Johnson & Johnson version of the COVID-19 vaccine, warning of a potentially serious autoimmune nerve disorder.
What’s the side effect?
In a bombshell report from The Washington Post, the outlet that broke the story, four sources familiar with the upcoming warning told the Post that the warning will revolve around a condition known as Guillain-Barré syndrome, which can develop into a serious medical condition if it’s not caught in time.
Reportedly, the warning will be based on roughly 100 confirmed cases of the serious condition, out of some 12.8 million Americans who’ve received the one-shot, J&J vaccine.
The company moved to get ahead of the public relations nightmare on Tuesday, issuing a statement in which they strongly emphasized the extremely rare chance that a J&J vaccine recipient would experience Guillain-Barré, a condition in which the body begins to attack its own nerve systems.
“The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree,” Johnson and Johnson said in a statement.
Fortunately, for those who’ve received either a Pfizer or Moderna vaccine, Guillain-Barré doesn’t seem to be a possibility, though there are other side effects that have been associated with those particular vaccinations.
CDC monitoring the situation
At the time of this writing, the FDA failed to respond to Fox News for comments on the developing situation, but the Centers for Disease Control and Prevention (CDC) acknowledge that it’s monitoring the latest developments.
“Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine,” a CDC spokesperson said on Tuesday.
“Very rarely, people have developed GBS in the days or weeks after receiving certain vaccines,” the agency said of the autoimmune condition. “The syndrome is estimated to affect about 1 in 100,000 people, and in the U.S. it is more common among men and individuals above age 50.”
The CDC went on to add that common treatment for Guillain-Barré includes a plasma exchange procedure or antibody infusions.
“While most people fully recover, some people have permanent nerve damage and the condition is particularly risky for those over 50, the CDC said,” the New York Post noted.